Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 2721-2730 Newer>

Managed Care February 2006 Martin Sipkoff	'Put All Your Drugs Into a Bag and Take It to Your Pharmacist' Health plans, with their view of the complete spectrum of patient care, are in a unique position to identify problems with polypharmacy.
Managed Care February 2006	CMO Pay Raises Averaged 9.9% in 2004-2005 Pay increases for chief medical officers have been pretty consistent from year to year.
Managed Care February 2006	For Drugs, the VA Pays Far Less Than Medicare A recent survey indicates that prices for the top 20 drugs used by Medicare enrollees are much higher than prices negotiated by the Department of Veterans Affairs.
Managed Care February 2006 Thomas Morrow	New Rheumatoid Arthritis Treatment Has Potential to Reduce Payer's Costs B-cells and their markers, once overlooked in the pathophysiology of rheumatoid arthritis, may hold the key for a new treatment regimen.
Managed Care February 2006	Health Care Plans & Providers to Invest Heavily in IT Services The payer market for health care IT will expand by a 7 percent compound annual rate over five years.
BusinessWeek March 6, 2006 Amy Barrett	Merck: Out Of The Ivory Tower Merck's pragmatic strategy includes tweaking the vitamin niacin to make it a blockbuster.
Bio-IT World February 2006 John Russell	Marvelous Models of Biological Systems Here are highlights from a roundtable discussion with researchers representing academia and pharmaceuticals, as well as executives from modeling technology providers on whether or not Pharma is ready to bet on computational modeling of biological systems.
Bio-IT World February 2006 Nancy Weil	The Evolving Boon of Bioinformatics As the heady days of cracking the human genome gave way to day-to-day work on a plethora of new drug targets, many bioinformaticians have reached a career crossroads, going to work for major consultancies, starting their own such small firms, or switching to academia.
Bio-IT World February 2006 Graeme O'Neill	GTG Celebrates Win Over Applera America's largest gene-testing company Applera agreed to license Australia's GTG's patented "junk DNA" gene-testing technology after a three-year battle. Applera will pay GTG about $11 million in the form of cash, equipment, and intellectual property.
Bio-IT World February 2006 Kevin Davies	Celera Drops Drugs for Diagnostics The company that raced to sequence the human genome, ditched its flamboyant CEO and database subscription model to become a drug development company, has decided to change course yet again.
<Older 2721-2730 Newer> Return to current articles.